Endotoxin Exposure to Examine the Role of Inflammation in Alcohol Use

The study design consists of a randomized, double-blind, placebo-controlled study of low dose endotoxin. Individuals with current AUD (n=32) and matched controls without AUD (n=32) will be randomly assigned to receive a single intravenous (I.V.) infusion of either low dose endotoxin (0.8 ng/kg of body weight) or placebo (same volume of 0.9% saline solution) to determine the acute and protracted role of inflammation in alcohol use.

NCT Number	NCT07452146
Lead Sponsor	University of California, Los Angeles Collaborators: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Conditions	Alcohol Use Disorder, Inflammatory Response, Craving
Enrollment	64 participants
Start Date	2026-06
Primary Completion	2028-06 (estimated)
Study Completion	2028-07 (estimated)
Updated on ClinicalTrials.gov	2026-05-04